Pam and her husband are parents of two children, one of whom was diagnosed with factor X deficiency soon after birth. After her initial shock, Pam became an advocate for her son, Reece, and has continued her strong advocacy for over 20 years. She hopes sharing her story about Reece moves other parents to advocate for early diagnosis and treatment for factor X deficiency.
Reece’s early days were a challenge, made more so by a severe brain bleed at 5 weeks of age. After being treated with fresh frozen plasma (FFP), Reece continued treatment twice weekly through a port placed in his chest. Over time, he struggled with the constant risk of infection in the port. At one point, he required hospitalization to overcome a serious infection.
Pam saw the value of being a strong partner with Reece’s health care team members. The doctors and nurses were family to her. Sharing their excitement when they told her COAGADEX was approved as treatment for hereditary factor X deficiency, she worked hard to ensure insurance coverage.
Pam proudly remembers the date in 2016 when Reece began his first COAGADEX infusion. She beams with confidence and gratitude that her son can self-infuse it in his arm over a shorter period of time.
Pam is grateful for the man her son has grown into, aided by her advocacy skills and COAGADEX. “I learned you might be only one voice, but you’ve got to stand up for yourself to be heard,” she said. Now she wants to share her story about Reece to inspire others on their factor X journeys.
Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild and moderate hereditary factor X deficiency
Limitation of Use
Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.
Contraindication for COAGADEX
COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.
Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.